Encompass Health Q2 2026: Revenue Up 9.6%, EPS $1.54, Raises Full-Year Outlook
EHC sits 35% above its 52-week low of $92.77 on light trading volume (0.3× avg).
Summary
Encompass Health reported Q2 2026 revenue of $1.6B (+9.6% YoY) and diluted EPS of $1.54, raised full-year guidance, and announced a dividend increase to $0.21/share.
Key Events · Earnings and Guidance · EHC
-
Q2 Revenue and Earnings Beat
Net operating revenues rose 9.6% to $1,597.4M, driven by a 5.6% increase in discharges and 3.9% higher net patient revenue per discharge. Diluted EPS was $1.54, up from $1.39 a year ago.
-
Full-Year Guidance Raised
Management raised its 2026 outlook, citing strong volume growth, favorable pricing, and a 2.3% Medicare rate increase effective October 1, 2026 under the 2027 Final IRF Rule.
-
Dividend Increased 10.5%
The board declared a quarterly cash dividend of $0.21 per share, up from $0.19, payable on October 15, 2026 to shareholders of record on October 1, 2026.
-
Active Capital Return Program
The company repurchased 1.4 million shares for $145.8M in H1 2026. The board reset the repurchase authorization to $1.0 billion on July 23, 2026.
Analysis · EHC · Industrial Applications And Services
Encompass Health delivered a strong second quarter, with revenue climbing 9.6% to $1.6 billion and adjusted EPS of $1.55 beating the $1.48 consensus. The company raised its full-year guidance, citing volume growth, favorable pricing, and a 2.3% Medicare rate increase effective October 1. The balance sheet remains robust after a $500 million debt refinancing that extended maturities, and the board boosted the quarterly dividend by 10.5% to $0.21 per share while repurchasing $145.8 million in stock during the first half. With 11 new hospitals in the pipeline and 150-200 bed additions planned, the growth trajectory is well-supported, though labor costs and regulatory risks around the Review Choice Demonstration bear watching.
At the time of this filing, EHC was trading at $125.19 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $12.4B. The 52-week trading range was $92.77 to $127.99. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.